keyword
MENU ▼
Read by QxMD icon Read
search

umeclidinium bromide vilanterol

keyword
https://www.readbyqxmd.com/read/27853383/uk-specific-cost-effectiveness-of-tiotropium-olodaterol-fixed-dose-combination-versus-other-lama-laba-combinations-in-patients-with-copd
#1
Abigail Tebboth, Andrew Ternouth, Nuria Gonzalez-Rojas
OBJECTIVE: The aim of this study is to assess the cost-effectiveness of other long-acting muscarinic antagonist + long-acting β2 agonist combinations in comparison with Spiolto(®) Respimat(®) (tiotropium + olodaterol fixed-dose combination [FDC]) for maintenance treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. METHODS: A previously published individual-level Markov model was adapted for the perspective of the UK health care system, in line with recommendations from the National Institute for Health and Care Excellence...
2016: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/27578968/correct-usage-ease-of-use-and-preference-of-two-dry-powder-inhalers-in-patients-with-copd-analysis-of-five-phase-iii-randomized-trials
#2
John H Riley, Maggie Tabberer, Nathalie Richard, Alison Donald, Alison Church, Stephanie S Harris
BACKGROUND: Handheld inhalers are used to deliver treatment for COPD. Incorrect usage leads to suboptimal disease control. Complex treatment regimens and use of multiple inhalers may reduce patient compliance. The Anoro Ellipta™ dry powder inhaler (DPI) simultaneously delivers umeclidinium bromide (UMEC) and vilanterol (VI) without coformulation being required. AIM: To assess the correct usage and ease of use of the Ellipta™ DPI administering UMEC/VI and to compare patient preference for Ellipta™ with the HandiHaler(®) through exploratory analyses of patient and observer questionnaires in five Phase III studies...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/27254953/-lama-laba-fixed-dose-combination-for-treatment-of-copd
#3
REVIEW
Ichiro Kuwahira
Several new fixed-dose combination bronchodilators have been launched in the world, and 3 different types are now available in Japan. Assessing their efficacy relative to each other has not been performed yet. In the present manuscript, characteristics of glycopyrronium/indacaterol, umeclidinium/vilanterol and tiotropium/olodaterol were reviewed. In particular, changes in trough and peak forced expiratory volume in 1 second (FEV1), St George's Respiratory Questionnaire (SGRQ) total scores, and transitional dyspnea index (TDI) focal scores were reviewed in these bronchodilators...
May 2016: Nihon Rinsho. Japanese Journal of Clinical Medicine
https://www.readbyqxmd.com/read/27143334/vilanterol-trifenatate-for-the-treatment-of-copd
#4
Mario Malerba, Alessandro Radaeli, Paolo Montuschi, Jaymin B Morjaria
INTRODUCTION: Currently the treatment of chronic obstructive pulmonary disease (COPD) has limited effectiveness and there is a need to develop new drugs. International guidelines recommend the use of long-acting bronchodilators (β2 agonists and anti-cholinergics/muscarinics), inhaled steroids and associations between these drugs in the maintenance treatment of moderate-to-severe COPD. AREA COVERED: Vilanterol trifenate is a new once-daily highly selective β2-agonist available in USA and Europe in association with umeclidinium bromide (a long-acting anti-muscarnic agent) and fluticasone furoate (an inhaled corticosteroid) for the once-daily maintenance treatment of COPD...
July 2016: Expert Review of Respiratory Medicine
https://www.readbyqxmd.com/read/27022659/-current-optimization-of-combined-therapy-for-chronic-obstructive-pulmonary-disease
#5
REVIEW
E N Popova
Testing the new combined bronchodilator Anoro Ellipta in different clinical trials gives to its high clinical efficacy and safety in chronic obstructive pulmonary disease. The drug contains the molecules of sustained-release selective β2-adrenergic receptor agonist (vilanterol) and a muscarinic cholinergic receptor antagonist (umeclidinium bromide). The bronchodilating mechanisms of umeclidinium bromide are in the competitive inhibition of the binding of acetylcholine with muscarinic acetylcholine receptors of airway smooth muscles whereas in those of vilanterol are in that with the stimulation of intracellular adenylate cyclase...
2015: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/26692823/cost-effectiveness-of-umeclidinium-vilanterol-combination-therapy-compared-to-tiotropium-monotherapy-among-symptomatic-patients-with-chronic-obstructive-pulmonary-disease-in-the-uk
#6
Yogesh Suresh Punekar, Graeme Roberts, Afisi Ismaila, Martin O'Leary
BACKGROUND: The cost-effectiveness of umeclidinium bromide-vilanterol (UMEC/VI) versus tiotropium monotherapy in the UK was assessed using a UMEC/VI treatment-specific economic model based on a chronic obstructive pulmonary disease (COPD) disease-progression model. METHODS: The model was implemented as a linked-equation model to estimate COPD progression and associated health service costs, and its impact on quality-adjusted life years (QALYs) and survival. Statistical risk equations for clinical endpoints and resource use were derived from the ECLIPSE and TORCH studies, respectively...
2015: Cost Effectiveness and Resource Allocation: C/E
https://www.readbyqxmd.com/read/26648622/umeclidinium-bromide-with-vilanterol
#7
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
April 2015: Australian Prescriber
https://www.readbyqxmd.com/read/26366803/dual-bronchodilator-therapy-with-aclidinium-bromide-formoterol-fumarate-for-chronic-obstructive-pulmonary-disease
#8
REVIEW
Tony D'Urzo, James F Donohue, David Price, Marc Miravitlles, Edward Kerwin
Inhaled bronchodilator therapy is a mainstay of treatment for chronic obstructive pulmonary disease (COPD). Despite the number and types of treatments available, the control of symptoms and exacerbations remains suboptimal, and adherence to, and persistence with, inhaled therapy is generally poor. Results from clinical studies suggest that dual bronchodilator therapy with long-acting muscarinic receptor antagonists (LAMAs) and long-acting β2 adrenergic receptor agonists (LABAs) may provide additional benefit over LAMA or LABA monotherapy without additive effects on safety and tolerability...
October 2015: Expert Review of Respiratory Medicine
https://www.readbyqxmd.com/read/25848294/umeclidinium-bromide-vilanterol-combination-in-the-treatment-of-chronic-obstructive-pulmonary-disease-a-review
#9
REVIEW
Dionisios Spyratos, Lazaros Sichletidis
Chronic obstructive pulmonary disease (COPD) is a common disease among the elderly that could be prevented by smoking cessation. As it is characterized by airflow limitation that is not fully reversible, bronchodilator therapy is the first choice of treatment. Symptomatic COPD patients with or without risk for future exacerbations have a strong indication for the permanent use of long- and ultralong-acting β2-agonists and/or long-acting muscarinic antagonists. Combining bronchodilators is an effective approach, as they demonstrate synergic action at a cellular level and have additive clinical benefits and fewer adverse events compared with increased doses of the monocomponents...
2015: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/25798635/a-systematic-review-of-the-efficacy-and-safety-of-a-fixed-dose-combination-of-umeclidinium-and-vilanterol-for-the-treatment-of-copd
#10
REVIEW
Gustavo J Rodrigo, Hugo Neffen
BACKGROUND: COPD guidelines recommend the combined use of inhaled long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) if symptoms are not improved by a single agent. This systematic review tested the hypothesis that the bronchodilator effect of the LABA/LAMA combination, umeclidinium (UMEC)/vilanterol (VIL), would translate into better outcomes without incurring increased adverse events (AEs). METHODS: This was a systematic review of randomized, placebo-controlled or crossover trials (> 4 weeks) involving UMEC/VIL compared with its monocomponents, tiotropium, or fluticasone/salmeterol...
August 2015: Chest
https://www.readbyqxmd.com/read/25754881/clinicopharmacological-profile-of-the-fixed-dose-combination-of-aclidinium-bromide-and-formoterol-fumarate-in-the-management-of-chronic-obstructive-pulmonary-disease
#11
REVIEW
K Suresh Babu, Jaymin B Morjaria
The recent Global Initiative for Chronic Obstructive Lung Disease (GOLD) chronic obstructive pulmonary disease (COPD) guidelines consider symptoms and exacerbation history in addition to the degree of airflow obstruction for classifying patients. The improvement of symptoms is principally provided by bronchodilators, using β2 agonists and antimuscarinic agents. Aclidinium bromide is a novel long-acting antimuscarinic agent licensed for use in patients with COPD. Novel fixed-dose combinations that are either licensed or in their late phase of development include vilanterol/umeclidinium, indacaterol/glycopyrronium, olodaterol/tiotropium and formoterol/aclidinium...
April 2015: Therapeutic Advances in Respiratory Disease
https://www.readbyqxmd.com/read/25673975/patient-considerations-in-the-treatment-of-copd-focus-on-the-new-combination-inhaler-umeclidinium-vilanterol
#12
REVIEW
Timothy E Albertson, Richart Harper, Susan Murin, Christian Sandrock
Medication adherence among patients with chronic diseases, such as COPD, may be suboptimal, and many factors contribute to this poor adherence. One major factor is the frequency of medication dosing. Once-daily dosing has been shown to be an important variable in medication adherence in chronic diseases, such as COPD. New inhalers that only require once-daily dosing are becoming more widely available. Combination once-daily inhalers that combine any two of the following three agents are now available: 1) a long-acting muscarinic antagonist; 2) a long acting beta2 agonist; and 3) an inhaled corticosteroid...
2015: Patient Preference and Adherence
https://www.readbyqxmd.com/read/25598422/umeclidinium-vilanterol-combination-inhaler-efficacy-and-potential-impact-on-current-chronic-obstructive-pulmonary-disease-management-guidelines
#13
REVIEW
James F Davidson, James F Donohue, Jill A Ohar
INTRODUCTION: Umeclidinium bromide (UM) with vilanterol (VI) is the first once-daily long-acting muscarinic antagonist/long-acting β2 agonist (LAMA/LABA) combination approved for use in the treatment of chronic obstructive pulmonary disease (COPD) in the USA. Prior to this, only combinations of short-acting bronchodilators and short-acting muscarinic antagonists were available in the USA as a single inhaler and they required frequent dosing. LAMA or LABA therapy is the recommended first choice for moderate-to-very severe COPD with combination therapy added if monotherapy fails to control patients' symptoms...
February 2015: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/25587755/bronchodilating-drugs-for-chronic-obstructive-pulmonary-disease-current-status-and-future-trends
#14
Paolo Montuschi, Giovanni Ciabattoni
Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological treatment of stable chronic obstructive pulmonary disease (COPD). Among approved LAMA, tiotropium bromide, glycopyrronium bromide, and umeclidinium bromide are administered once daily, whereas aclidinium bromide is administered every 12 h. New LAMA are under development for COPD. Among the approved LABA, indacaterol has a 24 h duration of action, whereas salmeterol and formoterol require twice-daily administration...
May 28, 2015: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/25458157/efficacy-and-safety-of-umeclidinium-vilanterol-62-5-25-mcg-and-tiotropium-18-mcg-in-chronic-obstructive-pulmonary-disease-results-of-a-24-week-randomized-controlled-trial
#15
RANDOMIZED CONTROLLED TRIAL
M Reza Maleki-Yazdi, Thomas Kaelin, Nathalie Richard, Michael Zvarich, Alison Church
BACKGROUND: Combinations of inhaled long-acting bronchodilator therapies such as muscarinic antagonists and β2-agonists may be more effective than monotherapy in the treatment of chronic obstructive pulmonary disease (COPD). METHODS: This study was a 24-week, Phase III, multicenter, randomized, blinded, double-dummy, parallel-group study of the once-daily, inhaled, fixed-dose combination of the long-acting muscarinic antagonist umeclidinium bromide and the long-acting β2-agonist vilanterol (UMEC/VI 62...
December 2014: Respiratory Medicine
https://www.readbyqxmd.com/read/25398674/umeclidinium-vilanterol-a-review-of-its-use-as-maintenance-therapy-in-adults-with-chronic-obstructive-pulmonary-disease
#16
REVIEW
Hannah A Blair, Emma D Deeks
Umeclidinium/vilanterol (Anoro(®) Ellipta™; Laventair™) is an inhaled fixed-dose combination of a long-acting muscarinic receptor antagonist and a long-acting β2-adrenoceptor agonist. It is available in several countries, including Japan, the USA, Canada and those of the EU, where it is indicated for oral inhalation in adults with chronic obstructive pulmonary disease (COPD). Umeclidinium/vilanterol is administered once daily using the Ellipta™ multi-dose dry powder inhaler, which is regarded as easy to use...
January 2015: Drugs
https://www.readbyqxmd.com/read/25382021/umeclidinium-bromide-vilanterol-for-the-treatment-of-chronic-obstructive-pulmonary-disease
#17
REVIEW
Maria Gabriella Matera, Paola Rogliani, Barbara Rinaldi, Mario Cazzola
A solid scientific rationale and an increasing body of clinical evidence fully support the use of an antimuscarinic agent combined with a β-agonist in chronic obstructive pulmonary disease. In this article, we focus on the development of an inhaled fixed dose combination (FDC) of two 24-h bronchodilators, umeclidinium bromide and vilanterol (UMEC/VI) (ANORO). Several pivotal clinical trials have documented the impact of this combination on lung function and other outcome measures such as quality of life, dyspnea, rescue medication use and exercise capacity, with no clinically meaningful treatment-related changes in vital signs or clinical laboratory parameters...
January 2015: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/25312239/umeclidinium-for-the-treatment-of-chronic-obstructive-pulmonary-disease
#18
REVIEW
Andrea Segreti, Luigino Calzetta, Paola Rogliani, Mario Cazzola
Umeclidinium is a novel inhaled long-acting muscarinic receptor antagonist (LAMA) approved for treatment of chronic obstructive pulmonary disease (COPD). It provides a bronchodilation of at least 24 h, is well tolerated and has a safe profile. In this article, we describe its pharmacokinetic and pharmacodynamic characteristics. Moreover, we present a meta-analysis of randomized clinical trials carried out in COPD patients, in which the change of forced expiratory volume in 1 s (FEV1) induced by umeclidinium has been compared with that elicited by placebo or the active compound tiotropium...
December 2014: Expert Review of Respiratory Medicine
https://www.readbyqxmd.com/read/25063267/umeclidinium-bromide-vilanterol-trifenatate-perampanel-and-eslicarbazepine-acetate
#19
Daniel A Hussar, Nabil Dharsi
No abstract text is available yet for this article.
July 2014: Journal of the American Pharmacists Association: JAPhA
https://www.readbyqxmd.com/read/25061288/differential-pharmacology-and-clinical-utility-of-emerging-combination-treatments-in-the-management-of-copd-role-of-umeclidinium-vilanterol
#20
REVIEW
Mario Malerba, Jaymin Bhagwanji Morjaria, Alessandro Radaeli
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease characterized by airflow limitation that is not fully reversible. Bronchodilator therapy is the cornerstone in COPD treatment. Bronchodilation in COPD is mainly achieved via administration of long- and ultralong-acting β2-agonists and with long-acting muscarinic antagonists. New combinations of bronchodilators with dual-acting muscarinic antagonist and β2-agonist properties have been licensed, and others are currently being developed with the aim of achieving once-daily dosing, and therefore may improve the likelihood of treatment compliance...
2014: International Journal of Chronic Obstructive Pulmonary Disease
keyword
keyword
117206
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"